Predict value of tumor markers combined with interleukins for therapeutic efficacy and prognosis in ovarian cancer patients
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.This study shows that combining tumor markers (TMs) like CA125 with interleukins (ILs) improves ovarian cancer (OC) treatment evaluation and prognosis. Monitoring these biomarkers aids in adjusting therapies for better patient outcomes.
Area Of Science
- Oncology
- Biochemistry
- Clinical Diagnostics
Background
- Ovarian cancer (OC) is a leading cause of cancer death in women, often diagnosed late.
- Current treatments lack significant survival improvements, necessitating novel prognostic and therapeutic biomarkers.
- Tumor markers (TMs) and interleukins (ILs) show potential for evaluating OC treatment efficacy and patient prognosis.
Purpose Of The Study
- To assess the combined diagnostic and prognostic value of TMs (CA125, AFP, CEA) and ILs (IL-1β, IL-2, IL-6, IL-8, IL-10) in ovarian cancer.
- To establish a predictive model for patient mortality in ovarian cancer.
- To explore the role of these biomarkers in monitoring treatment response.
Main Methods
- Retrospective analysis of 184 ovarian cancer patients.
- Quantification of serum CA125, AFP, CEA, and ILs using chemiluminescence and ELISA.
- Statistical analysis including Cox regression and Nomogram model construction.
Main Results
- Significant post-treatment decreases observed in CA125, AFP, CEA, IL-1β, IL-2, IL-6, and IL-10.
- Elevated CA125, IL-6, and IL-8 levels were associated with higher mortality.
- CA125, IL-8, histological grade, ascites, tumor thrombus, and FIGO stage were independent prognostic factors.
Conclusions
- Combined TMs and ILs offer significant value in evaluating OC therapeutic efficacy and prognosis.
- Dynamic monitoring of CA125, IL-6, and IL-8 can guide clinical decisions and improve prognostic reliability.
- A Nomogram model incorporating these factors demonstrated strong predictive ability for mortality (AUC=0.756).
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
Related Concept Videos
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...